Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
In the post-pandemic COVID-19 period, human activities have returned to normal and
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …
COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches
S Kakavandi, B Hajikhani, P Azizi, F Aziziyan… - Cell Communication and …, 2024 - Springer
Extensive research in countries with high sociodemographic indices (SDIs) to date has
shown that coronavirus disease 2019 (COVID-19) may be directly associated with more …
shown that coronavirus disease 2019 (COVID-19) may be directly associated with more …
Immunologic effect of bivalent mRNA booster in patients undergoing hemodialysis
L Huth, L Schäfer, G Almanzar, G Lupoli… - … England Journal of …, 2023 - Mass Medical Soc
Bivalent SARS-CoV-2 Booster in Hemodialysis Patients In a group of patients undergoing
hemodialysis who had received four previous inoculations of SARS-CoV-2 vaccines, a fifth …
hemodialysis who had received four previous inoculations of SARS-CoV-2 vaccines, a fifth …
Venetoclax in relapsed or refractory hairy-cell leukemia
E Tiacci, L De Carolis, A Santi… - New England Journal of …, 2023 - Mass Medical Soc
Venetoclax in Relapsed or Refractory Hairy-Cell Leukemia | New England Journal of Medicine
Skip to main content The New England Journal of Medicine homepage Advanced Search …
Skip to main content The New England Journal of Medicine homepage Advanced Search …
Cytokine-responsive T-and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients
JC Enssle, J Campe, A Moter, I Voit, A Gessner, W Yu… - Leukemia, 2024 - nature.com
Patients with multiple myeloma (MM) routinely receive mRNA-based vaccines to reduce
COVID-19-related mortality. However, whether disease-and therapy-related alterations in …
COVID-19-related mortality. However, whether disease-and therapy-related alterations in …
Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial
S Huang, X Zhang, Y Su, C Zhuang, Z Tang, X Huang… - The Lancet, 2024 - thelancet.com
Summary Background Hepatitis E virus (HEV) is a frequently overlooked causative agent of
acute hepatitis. Evaluating the long-term durability of hepatitis E vaccine efficacy holds …
acute hepatitis. Evaluating the long-term durability of hepatitis E vaccine efficacy holds …
Targeting enhanced neutralizing antibody responses via increased germinal center activity: early-phase vaccine trials with novel clinical designs
WO Hahn, JA Hill, JG Kublin - Current Opinion in HIV and AIDS, 2023 - journals.lww.com
Targeting enhanced neutralizing antibody responses via incre... : Current Opinion in HIV and
AIDS Targeting enhanced neutralizing antibody responses via increased germinal center …
AIDS Targeting enhanced neutralizing antibody responses via increased germinal center …
Clinical features and risk stratification of multiple myeloma patients with COVID-19
R Zheng, K Mieth, C Bennett, C Miller, LD Anderson Jr… - Cancers, 2023 - mdpi.com
Simple Summary This study is about how COVID-19 affects patients with multiple myeloma
(MM), a type of cancer, and aims to provide guidance for managing their risk and treatment …
(MM), a type of cancer, and aims to provide guidance for managing their risk and treatment …
Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron Variants
A Wagner, E Garner-Spitzer, C Auer, P Gattinger… - Vaccines, 2024 - mdpi.com
Patients with multiple myeloma (MM) are a heterogenous, immunocompromised group with
increased risk for COVID-19 morbidity and mortality but impaired responses to primary …
increased risk for COVID-19 morbidity and mortality but impaired responses to primary …
SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition
C Fischer, E Willscher, L Paschold, C Gottschick… - npj Vaccines, 2024 - nature.com
The rapid development of safe and effective vaccines helped to prevent severe disease
courses after SARS-CoV-2 infection and to mitigate the progression of the COVID-19 …
courses after SARS-CoV-2 infection and to mitigate the progression of the COVID-19 …